Reuters logo
BRIEF-Flamel Technologies reaches agreement with FDA on protocol for phase III pivotal trial of FT218
October 6, 2016 / 11:42 AM / in a year

BRIEF-Flamel Technologies reaches agreement with FDA on protocol for phase III pivotal trial of FT218

Oct 6 (Reuters) - Flamel Technologies SA :

* Flamel Technologies reaches agreement with fda on protocol for phase III pivotal trial of FT218

* Phase III trial commenced patient enrollment in canada, with sites in Europe and U.S. to be initiated near-term

* Says agreement was reached through special protocol assessment process Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below